Abiopharma

🔍 LINK WILLIAM J PHD (Director)

Company: Tarsus Pharmaceuticals, Inc. (TARS)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Sold 10,572 shares of Common Stock at $61.97 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 108,714.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,928 shares of Common Stock at $62.94 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 106,786.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
• F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.67 to $62.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $62.68 to $63.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.